Format

Send to

Choose Destination
Mol Cell Endocrinol. 2018 Nov 5;475:4-9. doi: 10.1016/j.mce.2018.02.001. Epub 2018 Feb 6.

Regulatory identification of BPA as an endocrine disruptor: Context and methodology.

Author information

1
ANSES, Risk Assessment Department, Maisons-Alfort, France.
2
DSEST, School of Public Health, University of Montreal, Quebec, Canada.
3
INRA, Toxalim, UMR1331, Toulouse, France.
4
LABERCA, UMR 1329, INRA-Oniris Nantes, France.
5
CNRS, France.
6
Human Biomonitoring Research Unit, Luxembourg Institute of Health, Luxembourg.
7
INERIS, Unité Modèles pour l'Ecotoxicologie et la Toxicologie (METO), Parc ALATA BP2, 60550 Verneuil en Halatte, France.
8
INRA, Laboratoire de Toxicologie Environnementale, UR 406 A&E, CS 40509, 84914 Avignon Cedex 9, France.
9
Centre des Sciences du Goût et de l'Alimentation, INRA, CNRS, agrosup, Université de Bourgogne - Franche-Comté, Dijon, 21000, France.
10
University Hospital of Nice, France & INSERM UMR U1065 - Centre Méditerranéen de Médecine Moléculaire, Nice, France.
11
Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), UMR_S 1085, F-35000 Rennes, France.
12
Centre de Référence sur les Agents Tératogènes (CRAT), AP-HP Armand Trousseau Hospital, Paris, France.
13
CECOS, AP-HP, Paris Seine-Saint-Denis University Hospitals, Jean Verdier Hospital, Paris, France.
14
Genetic Stability, Stem Cells and Radiations, CEA, INSERM U 967, University Paris-Diderot, CEA Research Center, 92265 Fontenay aux Roses, France.
15
CREFRE, Toulouse University, INSERM, Toulouse Veterinary School, 23 chemin des Capelles, BP 87614, F310176 Toulouse Cedex 3, France.
16
Univ-Lyon, CarMeN Laboratory, INSERM U1060, INRA U1397, Université Claude Bernard Lyon1, INSA Lyon, Charles Mérieux Medical School, F-69600 Oullins, France.
17
Sorbonne Universités, UPMC Univ Paris 06, INSERM, CNRS, Neuroscience Paris Seine - Institut de Biologie Paris Seine, 75005 Paris, France.
18
Laboratory of Ecotoxicology, UMR INERIS SEBio, Normandie Université, BP 540, 76058 Le Havre, France.
19
Calbinotox, Faculté des Sciences et Technologies, Université de Lorraine, 54500, Vandoeuvre les Nancy, France.
20
INSERM, France.
21
Toxalim (Research Centre in Food Toxicology), INRA, ENVT, INP-Purpan, UPS, Toulouse, France.
22
ANSES, Risk Assessment Department, Maisons-Alfort, France. Electronic address: elodie.pasquier@anses.fr.

Abstract

BPA is one of the most investigated substances for its endocrine disruptor (ED) properties and it is at the same time in the center of many ED-related controversies. The analysis on how BPA fits to the regulatory identification as an ED is a challenge in terms of methodology. It is also a great opportunity to test the regulatory framework with a uniquely data-rich substance and learn valuable lessons for future cases. From this extensive database, it was considered important to engage in a detailed analysis so as to provide specific and strong evidences of ED while reflecting accurately the complexity of the response as well the multiplicity of adverse effects. An appropriate delineation of the scope of the analysis was therefore critical. Four effects namely, alterations of estrous cyclicity, mammary gland development, brain development and memory function, and metabolism, were considered to provide solid evidence of ED-mediated effects of BPA.

KEYWORDS:

Bisphenol A; ED; Endocrine disruption; REACh; SVHC; Substance of very high concern

PMID:
29426018
DOI:
10.1016/j.mce.2018.02.001
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for HAL archives ouvertes
Loading ...
Support Center